Abstract
Introduction: While there is extensive literature on HPA system activity in acutely depressed patients, there is only limited information about the presence of hypercortisolemia during the interepisode interval of affective disorders. We hypothesized an increase in HPA system activity in depressed patients compared to controls, and proposed that night-time cortisol excretion during follow-up will depend on clinical outcome.
Methods: We measured night-time cortisol excretion in 27 patients during an acute episode of major depression as well as a 20-week follow-up. 40 healthy subjects served as control group.
Results: During the acute episode depressed patients showed increased levels of night-time cortisol excretion compared to healthy controls. Both, patients with full and sustained remission (n=8) as well as patients with incomplete remission or relapse (n=19) showed declining cortisol excretion in night-time urine during follow-up. At the end of follow-up cortisol excretion did not differ between patients with affective disorder and healthy controls.
Discussion: Irrespective of residual depressive symptoms, HPA system activity declines after the generally investigated acute depressive episode.
References
1
Ahrens T, Deuschle M, Krumm B. et al .
Pituitary-adrenal and sympathetic nervous system responses to stress in women remitted from major depression.
Psychosomatic Med.
2008;
70
461-467
2
Brown ES, Varghese FP, McEwen BS.
Association of depression with medical illness: does cortisol play a role?.
Biol Psychiatry.
2004;
55
1-9
3
Bschorr T, Baethge C, Adli M. et al .
Lithium augmentation increases post-dexamethasone cortisol in the dexamethasone suppression test in unipolar major depression.
Depression and Anxiety.
2003;
17
43-48
4
Colla M, Kronenberg G, Deuschle M. et al .
Hippocampal volume reduction and HPA system activity in major depression.
J Psychiatr Res.
2007;
41
553-560
5
Deshauer D, Grof E, Alda M. et al .
Patterns of DST positivity in remitted affective disorders.
Biol Psychiatry.
1999;
45
1023-1029
6
Enns MW, Larsen DK, Cox B.
Discrepancies between self and observer ratings of depression. The relationship to demographic, clinical and personality variables.
J Affective Disord.
2000;
60
33-41
7
Hatzinger M, Hemmeter UM, Baumann K. et al .
The combined DEX-CRH test in treatment course and long-term outcome of major depression.
J Psychiatric Res.
2002;
36
287-297
8
Judd LL, Akiskal HS, Maser JD. et al .
A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders.
Arch Gen Psychiatry.
1998;
54
989-991
9
Kathol RG.
Persistent elevation of urinary free cortisol and loss of circannual periodicity in recovered depressive patients: a trait finding.
J Affective Disord.
1985;
8
137-145
10
Kloiber S, Ising M, Reppermund S. et al .
Overweight and obesity affect treatment response in major depression.
Biol Psychiatry.
2007;
62
321-326
11
Laakmann G, Hennig J, Baghai T. et al .
Influence of mirtazapine on salivary cortisol in depressed patients.
Neuropsychobiology.
2003;
47
31-36
12
Linkowski P, Mendlewicz J, Leclercq R. et al .
The 24-hour profile of adrenocorticotropin and cortisol in major depressive illness.
J Clin Endocrinol Metab.
1985;
61
429-438
13
Maes M, Lin A, Bonaccorso S. et al .
Increased 24-hour urinary cortisol excretion in patients with post-traumatic stress disorder and patients with major depression, but not in patients with fibromyalgia.
Acta Psychiatrica Scandinavica.
1998;
98
328-335
14
McEwen B.
Allostasis and allostatic load: implications for neuropsychopharmacology.
Neuropsychopharmacology.
2000;
22
108-124
15
Scharnholz B, Weber-Hamann B, Lederbogen F. et al .
Antidepressive treatment with mirtazapine, but not venlafaxine lowers cortisol concentrations in saliva: a randomised open trial.
Psychiatry Res.
in press
16
Schüle C, Baghai T, Bidlingmaier M. et al .
Endocrinological effects of mirtazapine in healthy volunteers.
Prog Neuropsychopharmacol Biol Psychiatry.
2002;
26
1253-1261
17
Schüle C, Baghai T, Rackwitz C. et al .
Influence of mirtazapine on urinary free cortisol excretion in depressed patients.
Psychiatry Res.
2003;
120
257-264
18
Schweiger U, Deuschle M, Körner A. et al .
Low lumbar bone mineral density in patients with major depression.
Am J Psychiatry.
1994;
151
1691-1693
19
Steiger A, Holsboer F.
Nocturnal secretion of prolactin and cortisol and the sleep EEG in patients with major endogenous depression during an acute episode and after full remission.
Psychiatry Res.
1997;
72
81-88
20
Vythilingam M, Vermetten E, Anderson GM. et al .
Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment.
Biol Psychiatry.
2004;
56
101-112
21
Weber-Hamann B, Kopf D, Lederbogen F. et al .
Activity of the hypothalamus-pituitary-adrenal system and oral glucose tolerance in depressed patients.
Neuroendocrinology.
2005;
81
200-204
22
Weber-Hamann B, Werner M, Hentschel F. et al .
Metabolic changes in elderly patients with major depression: evidence for increased accumulation of visceral fat at follow-up.
Psychoneuroendocrinology.
2006;
31
347-354
23
Yang TT, Hsiao FH, Wang KC. et al .
The effect of psychotherapy added to pharmacotherapy on cortisol responses in outpatients with major depressive disorder.
J Nerv Ment Dis.
2009;
197
401-406
24
Yehuda R, Halligan SL, Yang RK. et al .
Relationship between 24-hour urinary-free cortisol excretion and salivary cortisol levels sampled from awakening to bedtime in healthy subjects.
Life Sciences.
2003;
73
349-358
25
Zobel AW, Nickel T, Sonntag A. et al .
Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression A prospective study.
J Psychiatric Res.
2001;
35
83-94
Correspondence
M. DeuschleMD
Department of Psychiatry and Psychotherapy
Central Institute of Mental Health
J5
68159 Mannheim
Germany
Telefon: +49/621/1703 2331
Fax: +49/621/1703 2325
eMail: michael.deuschle@zi-mannheim.de